{"id":606170,"date":"2024-06-04T22:26:59","date_gmt":"2024-06-05T02:26:59","guid":{"rendered":"https:\/\/platohealth.ai\/holt-resignation-leaves-amarin-with-third-ceo-in-14-months\/"},"modified":"2024-06-05T04:42:04","modified_gmt":"2024-06-05T08:42:04","slug":"holt-resignation-leaves-amarin-with-third-ceo-in-14-months","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/holt-resignation-leaves-amarin-with-third-ceo-in-14-months\/","title":{"rendered":"Holt resignation leaves Amarin with third CEO in 14 months","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Plus: FNIH awards Lurie Prize to Stanford\u2019s Chang, and updates from Tectonic and Contineum<\/h2>\n

\n By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

June 5, 2024 2:26 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Patrick Holt has resigned <\/span>as president and CEO of  Amarin Corp. plc<\/a><\/b> (NASDAQ:AMRN) to pursue other opportunities, setting up EVP and President of the U.S. business unit Aaron Berg to become the cardiovascular company\u2019s third CEO since March 2023, when Karim Mikhail departed amid a proxy battle with Sarissa Capital. Berg, a 12-year veteran of the company, led the company after Mikhail\u2019s departure on an interim basis. He was previously CEO of Essentialis Inc. Shares of Amarin fell 18% Tuesday to $0.70, giving the company a market cap of about $290 million.<\/p>\n

The Foundation for the National Institutes of Health<\/a><\/b> awarded the 2024 Lurie Prize <\/span>in Biomedical Sciences to Howard Chang of Stanford University. Chang and his team uncovered the role of long non-coding RNA in gene regulation and its effect on diseases such as cancer and autoimmunity. Chang is a professor of cancer research, dermatology and genetics at Stanford and an investigator at Howard Hughes Medical Institute…<\/p>\n